Expertise in
2
conditions

Laure Favier

Dijon, FR 
Expertise in
2
conditions
Dijon, FR 

Overview

Laure Favier practices practicing medicine in Dijon, France.

Ms. Favier is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Testicular Yolk Sac Tumor.

She is actively involved in clinical research, co-authoring 56 peer reviewed articles and participating in 10 clinical trials.

Gender

Female

Locations

Dijon, France
Other Locations
Bourgogne, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
EWOC-1 Trial: Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer
EWOC-1 Trial: Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer
Enrollment Status: Completed
Publish Date: December 19, 2025
Intervention Type: Drug
Study Phase: Phase 2
Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drugs: Carboplatin-Paclitaxel, Dostarlimab
Study Phase: Phase 3
Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2024
Intervention Type: Drug
Study Drugs: OSE2101, Pembrolizumab [Keytruda]
Study Phase: Phase 2
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
Enrollment Status: Unknown
Publish Date: December 07, 2023
Intervention Type: Biological
Evaluation and Validation of Quality Of Life Scales in Palliative Advanced Cancer
Evaluation and Validation of Quality Of Life Scales in Palliative Advanced Cancer
Enrollment Status: Terminated
Publish Date: August 01, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Genetic
Study Phase: Not Applicable
Pemetrexed in Maintenance in Patients With Impaired Renal Function: Randomized Phase 4 Multicenter Study Comparing 2 Dose Calculation Strategies (PKAPIR)
Pemetrexed in Maintenance in Patients With Impaired Renal Function: Randomized Phase 4 Multicenter Study Comparing 2 Dose Calculation Strategies (PKAPIR)
Enrollment Status: Completed
Publish Date: May 24, 2021
Intervention Type: Drug
Study Drug: Pemetrexed
Study Phase: Phase 4
Characteristics of the Intestinal Microbiota in Patients With Cancer (Catalogue-Onco)
Characteristics of the Intestinal Microbiota in Patients With Cancer (Catalogue-Onco)
Enrollment Status: Completed
Publish Date: January 27, 2020
Intervention Type: Biological
Study Phase: Not Applicable
Prospective, Multicenter, Randomized Controlled Study Evaluating the Efficacy of Parenteral Nutrition on the Quality of Life and Overall Survival in Patients in the Palliative Phase of Cancer.
Prospective, Multicenter, Randomized Controlled Study Evaluating the Efficacy of Parenteral Nutrition on the Quality of Life and Overall Survival in Patients in the Palliative Phase of Cancer.
Enrollment Status: Completed
Publish Date: September 17, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

56 Total Publications

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.
Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.
Journal: Gynecologic oncology
Published: April 06, 2026

Frequently Asked Questions about Laure Favier

Is Laure Favier a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Laure Favier is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Laure Favier participate in research or clinical trials?

Yes. Laure Favier has published 56 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Laure Favier's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Favier's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile